This is an aggregated industry headline. Read the full story at FierceBiotech →
Spyre spies another edge for UC ambitions with midstage win for anti-TL1A antibody
The company's SPY002 prompted a 10.7-point reduction from baseline levels in patients' Robart's Histopathology Index (RHI) scores by week 12.
By FierceBiotech
· Jun 16, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Following criticism from drugmakers, Germany has scrapped its plan to install a program that would have reduce…
The WeekBriefing
The FDA approved Colorado’s proposal to import certain Canadian drugs, aiming to curb costs for state resident…
The WeekDrug Channels ↗
By Bryce Platt, PharmD For years, Medicare Part D plans often preferred high-list/high-rebate branded multiple…